2-Tert-butyl-4-ethyl-1-fluorobenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Tert-butyl-4-ethyl-1-fluorobenzene
• 英文别名: 2-tert-butyl-4-ethyl-1-fluorobenzene
• 化学式: C₁₂H₁₇F
• 分子量: 180.26
• InChiKey: OPSLGQZZOWNFMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：NUVATION BIO INC

  公开号：WO2020210375A1

  公开（公告）日：2020-10-15

  Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Weel抑制剂的杂环化合物。这些化合物可能作为治疗药物用于治疗疾病，并且在肿瘤学中可能发挥特定作用。
• NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
  申请人：FORMA THERAPEUTICS, INC.

  公开号：US20160002188A1

  公开（公告）日：2016-01-07

  The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

  本发明涉及用于抑制FASN的化合物和组合物，它们的合成，应用和解毒剂。本发明的一个示例化合物如下所示：
• Chemical compounds
  申请人：AstraZeneca AB

  公开号：US10221173B2

  公开（公告）日：2019-03-05

  The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.

  本说明书涉及式 (I) 化合物： 及其药学上可接受的盐、用于制备它们的工艺和中间体、含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
• US20140256717A1
  申请人：——

  公开号：US20140256717A1

  公开（公告）日：2014-09-11
• MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Fundación Centro Nacional de Investigaciones Oncologicas Carlos III

  公开号：US20160296528A1

  公开（公告）日：2016-10-13

  There is provided compounds of formula I, wherein R1, R 2a , R 2b , R 2c , X, Y, Z, R 3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.